MedPath
Found 2253 clinical trials|View Analysis
Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Placebo matching BI 3731579
First Posted Date
2024-12-04
Last Posted Date
2025-02-04
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
40
Registration Number
NCT06716190
Locations
🇧🇪

SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

Phase 1
Active, not recruiting
Conditions
Liver Diseases
Healthy
Interventions
Drug: Zongertinib (BI 1810631)
First Posted Date
2024-11-18
Last Posted Date
2025-06-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT06692322
Locations
🇺🇸

American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

Phase 2
Recruiting
Conditions
Compensated Liver Cirrhosis
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions
Drug: Placebo for BI 770371
First Posted Date
2024-11-05
Last Posted Date
2025-06-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT06675929
Locations
🇺🇸

Southern California Research Center, Coronado, California, United States

🇺🇸

Catalina Research Institute, LLC-Montclair-49051, Montclair, California, United States

🇺🇸

Knowledge Research Center, Orange, California, United States

and more 9 locations

A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-10-23
Last Posted Date
2025-03-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT06655220
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 690517 formulation 1
Drug: BI 690517 formulation 2
First Posted Date
2024-10-18
Last Posted Date
2025-01-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT06647810
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Phase 2
Recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: BI 3032950 intravenous (Part A)
Drug: BI 3032950 subcutaneous (Part B)
First Posted Date
2024-10-15
Last Posted Date
2025-06-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
40
Registration Number
NCT06636656
Locations
🇺🇸

Peak Gastroenterology Associates, Colorado Springs, Colorado, United States

🇧🇪

AZ Maria Middelares, Gent, Belgium

🇧🇪

UZ Leuven, Leuven, Belgium

and more 47 locations

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Phase 3
Recruiting
Conditions
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Interventions
Drug: Placebo
First Posted Date
2024-10-09
Last Posted Date
2025-06-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1800
Registration Number
NCT06632444
Locations
🇺🇸

Arizona Liver Health-Chandler-68733, Chandler, Arizona, United States

🇺🇸

The Institute for Liver Health, LLC, Tucson, Arizona, United States

🇺🇸

Arizona Liver Health - Peoria 85381, Peoria, Arizona, United States

and more 459 locations

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Phase 3
Recruiting
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Drug: Placebo matching survodutide
First Posted Date
2024-10-09
Last Posted Date
2025-06-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1590
Registration Number
NCT06632457
Locations
🇪🇸

Hospital La Paz, Madrid, Spain

🇪🇸

Hospital Puerta de Hierro, Majadahonda, Spain

🇨🇳

Tianjin Second People's Hospital, Tianjin Shi, China

and more 423 locations

A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2024-10-08
Last Posted Date
2025-06-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT06631430
Locations
🇧🇪

SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-10-08
Last Posted Date
2025-05-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT06631417
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath